Evidence map›Paper›PMID 40613215›Full record

ArticleFuture medicinal chemistry2025

Synthesis, antiproliferative evaluation and

Abdelsalam Mohamed Abdelsalam Ouf, Adel A Marzouk, Montaser Sh A Shaykoon, Ismail Celik, Dina A Bakhotmah, Ahd A Mansour, Mariam K Alamoudi, Abdallah M Alfayomy, Mohamed Ayman El-Zahabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdelsalam Mohamed Abdelsalam OufPharmaceutical Medicinal Chemistry& Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.ORCID 0000-0002-3794-3403
Adel A MarzoukPharmaceutical Medicinal Chemistry& Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.ORCID 0000-0003-4864-2056
Montaser Sh A ShaykoonPharmaceutical Medicinal Chemistry& Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.ORCID 0000-0003-4044-9120
Ismail CelikPharmaceutical Chemistry Department, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.ORCID 0000-0002-8146-1663
Dina A BakhotmahDepartment of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0001-6651-7932
Ahd A MansourMedical Laboratory Science Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.ORCID 0000-0003-3729-4770
Mariam K AlamoudiDepartment of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.ORCID 0000-0001-7653-0401
Abdallah M AlfayomyPharmaceutical Medicinal Chemistry& Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.ORCID 0000-0003-3704-5483
Mohamed Ayman El-ZahabiPharmaceutical Medicinal Chemistry& Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID 0000-0003-4538-5840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew quinazoline derivatives were designed and synthesized to target VEGFR-2, aiming to identify potential anticancer agents. RESEARCH DESIGN AND

methodsThe synthesized compounds underwent

resultsCompounds

conclusionsCompounds

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolinesVascular Endothelial Growth Factor Receptor-2ApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsKDR protein, humanProtein Kinase InhibitorsQuinazolinesVascular Endothelial Growth Factor Receptor-2ADMETAngiogenesisAntiproliferativeCell cycle arrestQuinazolineVEGFR-2

Identifiers

PMID40613215
PMCPMC12296094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.